Premium
Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis
Author(s) -
Warren R.B.,
Barker J.N.W.,
Van de Kerkhof P.,
Reich K.,
Mrowietz U.
Publication year - 2019
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.15644
Subject(s) - medicine , psoriasis , placebo , dimethyl fumarate , fumaric acid , plaque psoriasis , psoriasis area and severity index , adverse effect , dermatology , immunology , alternative medicine , pathology , chemistry , multiple sclerosis , organic chemistry
Psoriasis is a chronic inflammatory skin disorder with a significant disease burden. While numerous treatments exist, development of effective and affordable therapies offering good patient outcomes remains desirable. A mixture of fumaric acid esters (FAE) is commonly prescribed for oral treatment of moderate-to-severe plaque psoriasis in Germany. In other European countries (UK, Ireland, Italy, and the Netherlands, among others), FAE have been imported or compounded by local pharmacies. Current international guidelines recommend FAE for the short- and long-term management of psoriasis. Although the original formulation (Fumaderm ) contains a mixture of FAE, the main active ingredient is dimethylfumarate (DMF), an anti-inflammatory and immune-modulating agent with proven efficacy in psoriasis. The monoethylfumarate salts within the FAE formulation have shown much lower biological activity both in vitro and in vivo. This article is protected by copyright. All rights reserved.